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Coordinated repression of BIM and PUMA by
Epstein–Barr virus latent genes maintains the
survival of Burkitt lymphoma cells
Leah Fitzsimmons*,1, Andrew J Boyce1, Wenbin Wei1,2, Catherine Chang3,4, Deborah Croom-Carter1, Rosemary J Tierney1,
Marco J Herold3,4, Andrew I Bell1, Andreas Strasser3,4, Gemma L Kelly*,3,4,5 and Martin Rowe1,5
While the association of Epstein–Barr virus (EBV) with Burkitt lymphoma (BL) has long been recognised, the precise role of the
virus in BL pathogenesis is not fully resolved. EBV can be lost spontaneously from some BL cell lines, and these EBV-loss
lymphoma cells reportedly have a survival disadvantage. Here we have generated an extensive panel of EBV-loss clones from
multiple BL backgrounds and examined their phenotype comparing them to their isogenic EBV-positive counterparts. We report
that, while loss of EBV from BL cells is rare, it is consistently associated with an enhanced predisposition to undergo apoptosis
and reduced tumorigenicity in vivo. Importantly, reinfection of EBV-loss clones with EBV, but surprisingly not transduction with
individual BL-associated latent viral genes, restored protection from apoptosis. Expression profiling and functional analysis of
apoptosis-related proteins and transcripts in BL cells revealed that EBV inhibits the upregulation of the proapoptotic BH3-only
proteins, BIM and PUMA. We conclude that latent EBV genes cooperatively enhance the survival of BL cells by suppression of the
intrinsic apoptosis pathway signalling via inhibition of the potent apoptosis initiators, BIM and PUMA.
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Epstein–Barr virus (EBV)-positive Burkitt lymphoma (BL), an
aggressive and difficult to treat malignancy, is endemic (eBL)
in sub-Saharan Africa, where it accounts for around half of all
childhood lymphomas. BL also occurs worldwide at lower
incidence, and in these cases, known as sporadic BLs (spBL),
EBV is found in 15–85% of tumours, varying by geographical
region.1 The genetic hallmark of all BL is the chromosomal
translocation between the c-MYC gene and a constitutively
active immunoglobulin (Ig) gene promoter/enhancer. Typical
of c-MYC-driven lymphomas, BLs proliferate rapidly but are
also sensitive to apoptosis under conditions of stress.2
Cellular proapoptotic BH3-only proteins (e.g. BIM, PUMA,
BAD, NOXA) induce cell death by unleashing the proapoptotic
multi-BH domain executioner BCL-2 family members, BAK
and BAX, allowing them to form pores in the mitochondrial
outer membrane, which commits the cells to apoptosis. BH3-
only proteins can achieve this by binding and inhibiting
prosurvival BCL-2 family proteins (BCL-2, BCL-XL, BCL-W,
A1/BFL1 and MCL-1), which in the absence of an apoptotic
stimulus restrain BAK and BAX, thereby preventing cellular
destruction. Additionally, BIM, PUMA and tBID can directly
activate BAX and BAK (reviewed in Strasser et al.3). It was
shown using the Eμ-Myc transgenic mouse model of human
BL (which expresses a c-Myc;Ig transgene) that blocking
apoptosis through enforced expression of BCL-2 prosurvival
proteins or deletion of BH3-only proteins or BAX greatly
accelerates lymphoma development.4–7
In human BL it is not clear how EBV contributes to the
continued growth of the tumour. One view is that EBV
counteracts the cell death-promoting actions of aberrant
c-MYC expression. When EBV infects resting B cells in vitro,
it expresses the growth-transforming programme of latency
genes, termed Latency III, involving expression of 10 proteins
(EBNAs 1, 2, 3A, 3B, 3C and LP; LMPs 1, 2A and 2B; and the
viral BCL-2 homologue, BHRF1), two non-coding RNAs
(EBER1 and EBER2), and two families of microRNAs (BART
microRNAs (miR-BARTs) and miR-BHRF1s), which together
drive proliferation and promote cell survival (reviewed in Rowe
et al.8) (Figure 1).
Crucially, however, most of the Latency III genes are not
expressed in established BLs. Instead, in BLs, EBV exhibits
more restricted forms of latency characterised by expression
of EBNA1, the EBER transcripts and the miR-BARTs
(Figure 1). Only a minority of eBLs exhibit a more complex
viral gene expression pattern due to a genomic deletion in
EBV.9,10 Cell lines derived from these tumours show marked
resistance to apoptosis due to epigenetic silencing of the BIM
promoter11 and functional inhibition of BIM, PUMA, BID and
BAK by the viral BCL-2 homologue, BHRF1.12
EBV-positive and -negative BLs are genetically distinct,
differing in terms of their cellular mutational profiles13,14 and
precise Ig-MYC chromosomal translocations.15,16 It is there-
fore unsatisfactory to introduce the virus or viral genes into
EBV-negative spBL lines to study the role of EBV in eBL.
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Instead, efforts have focused on trying to rid EBV-positive
eBLs of the virus to assess the contribution of EBV to the
growth and survival of BL in an isogenic system. Treatment of
EBV-positive BL cells with a dominant-negative form of
EBNA1 leads to loss of EBV genomes and widespread
apoptosis.17–20 While implying that EBV is essential for the
continued survival of BL cells, this method yielded few EBV-
loss clones for mechanistic studies. Hydroxyurea treatment
can also eradicate EBV, but these BL clones do not show a
consistent apoptosis predisposition phenotype.21 Additionally,
an unusual EBV-positive spBL (Akata-BL) cell line has been
reported to spontaneously lose EBV in vitro, yielding clones
with impaired cell growth.22
A significant limitation of these previous studies has been
the small number of tumour backgrounds and/or clones
analysed. BL, like many cancers, can exhibit considerable
inter- and intratumoral genetic heterogeneity.23,24 The present
study resolves the unmet need for a systematic approach to
analyse multiple EBV-loss BL clones on several tumour
backgrounds both in vitro and in vivo in a xenograft model of
BL. Thiswork has shown unequivocally that EBV in a Latency I
infection can protect BL cells from apoptosis mediated by the
proapoptotic BH3-only proteins, BIM and PUMA.
Results
Determining the contribution of EBV to the continued
growth of BL cells. A panel of EBV-positive BL cell lines
(1 spBL and 11 eBLs) were seeded at single-cell dilutions to
establish more than 1800 clones. These clones were
screened for EBV episome copy number by quantitative,
real-time PCR (q-PCR); the results are summarised in
Table 1 and Figure 2a. Strikingly, the generation of EBV-
loss cells was a rare event, observed in only 61/1800 (3.4%)
clones and seven BL cell lines never yielded EBV-loss
clones. These results strongly indicate that while EBV is not
essential for continued BL cell growth, there is strong
selective pressure to retain EBV.
Before investigating the phenotype of the EBV-positive
clones, their EBV infection status was fully characterised. This
included flow cytometry for EBERs to confirm that all cells
carried the virus, as well as immunoblotting and q-PCR for 45
EBV transcripts to ensure that the clones retained Latency I
gene expression (EBNA1-positive, EBNA2- and LMP1-
negative, and low lytic cycle gene expression) (Figures 2b
and c and Supplementary Figure 1).
Effect of EBV loss on the tumorigenicity and survival
phenotype of BL clones. To assess the contribution of EBV
to BL growth in vivo, isogenic EBV-positive and EBV-loss
clones derived from three eBL backgrounds (Kem-BL, Mutu-
BL and Awia-BL), were transplanted by intraperitoneal
injection into female NSG mice and the animals monitored
for tumour burden. Tumours arose in the spleen, ovaries and
pancreas and resembled human BL in terms of pathology
and histological ‘starry sky’ appearance (Supplementary
Figure 2a). Across all tumour backgrounds, EBV-loss clones
were significantly less tumorigenic than their EBV-positive
counterparts. The median survival of EBV-positive versus
EBV-loss clones was 54versus 102 days for Kem-BL,
63versus 113 days for Mutu-BL and 50versus 68 days for
Awia-BL (Figure 3a). For direct comparison with previous
studies,22,25 clones of Akata-BL were transplanted by
subcutaneous injection into NSG mice at a higher inoculum.
The EBV-positive clones gave rise to tumours, whereas the
EBV-negative clones were non-tumorigenic in vivo
(Supplementary Figure 2b). Subsequent ex vivo analysis
confirmed that the Latency I gene expression pattern was
retained in all tumours derived from EBV-positive BL cells
(Supplementary Figure 2c).
Figure 1 Examples of patterns of EBV gene expression. Schematic showing the Latency III EBV gene expression programme (as found in B cells transformed in vitro into
lymphoblastoid cell lines (LCLs)) and the Latency I EBV gene expression programme (as found in the majority of EBV-positive BL tumours and cell lines derived from these
tumours). Latent proteins (EBNA1, EBNA2, EBNA3A, EBNA3B, EBNA3C, EBNA-LP, BHRF1, LMP1 and LMP2A/B) are shown in blue. Non-coding RNAs (EBERs, BHRF1
microRNAs and miR-BARTs) are shown in red, and latent promoters (Cp, Wp, Qp and LMP promoters) are shown in green
Table 1 Summary of single-cell cloning of BL cell lines
Cell line Genome load EBV-loss frequency
Range (median) Number Percentage
Eli-BL 0–68 (13) 38/103 36.90
Akata-BL 0–51 (13) 15/272 5.50
Kem-BL 0–300+ (35) 3/185 1.60
Mutu-BL 0–300+ (61) 3/195 1.50
Awia-BL 0–35 (9) 2/190 1.10
Ava-BL 6–68 (39) 0/158 —
Chep-BL 2–80 (2) 0/149 —
Dante-BL 11–68 (19) 0/95 —
Oku-BL 5–37 (8) 0/135 —
Rael-BL 7–300+ (43) 0/91 —
Sal-BL 6–30 (15) 0/72 —
Sav-BL 30–300+ (231) 0/175 —
Abbreviations: BL, Burkitt lymphoma; EBV, Epstein–Barr virus
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Figure 2 Genome loads and viral gene expression in BL single-cell clones. (a) Cells from each clonal cell line grown from a single cell by limiting dilution were harvested,
lysed and analysed by q-PCR to enumerate the average EBV genome copy number per cell. Quantitation was calculated relative to Namalwa-BL cells, which contain two
integrated copies of EBV per cell and these data were normalised to the housekeeping gene, β2M, of which diploid cells carry two copies. Clones of Dante-BL showed little
variation in EBV copy number and yielded no EBV-loss clones, whereas Mutu-BL and Kem-BL cells had more variable genome loads and yielded EBV-loss clones (denoted by an
asterisk). (b) Expression of EBV latent protein, EBNA1, in isogenic EBV-positive (P1-P2) and EBV-loss (n1-n2) BL clones. Probing for β-actin was used as a loading control. (c)
Transcription of Latency I-associated genes in EBV-positive clones of Akata-BL (◯), Awia-BL (&), Kem-BL (◇) and Mutu-BL (Δ) expressed relative to the endogenous control,
GAPDH, and shown relative to the range seen in a panel of eight Latency I BL cell lines (grey bracket), including those from which the EBV-loss clones were isolated, as described
elsewhere.53 EBNA2 expression is shown compared with the range seen in a panel of five LCLs (green bracket). EBNA1 refers to Q-U-K transcripts driven from the Qp promoter
that are indicative of Latency I. BARTs refers to BamHI A transcripts that are spliced between exons 1 and 3 (the excised RNA gives rise to miR-BARTs)
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To explain the loss of tumorigenic potential in vivo, isogenic
EBV-positive and EBV-loss clones were treated with
apoptosis-inducing agents in vitro to ascertain whether EBV
confers a survival advantage under stress conditions. EBV-
loss clones were consistently more sensitive to apoptosis
induced by BCR crosslinking or treatment with ionomycin,
roscovitine or staurosporine (Figures 3b and c and
Supplementary Figures 2a and 3a, b). Consistent with the
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finding that the TP53 tumour suppressor pathway is frequently
abrogated in human BL,26 there was no difference in survival
of the EBV-loss and EBV-positive clones following treatment
with the DNA damage inducers, etoposide and cisplatin
(Supplementary Figure 3c and data not shown). Furthermore,
all BL cloneswere resistant to agents that induce cell death via
the extrinsic apoptosis pathway (Supplementary Figure 4), in
agreement with published findings.27 These data suggest that
EBV confers a survival advantage to BL cells through
modulation of the intrinsic, BCL-2 family-regulated, apoptotic
pathway.
Effect of Latency I EBV genes on BL cell survival. The
literature mapping EBV protection to a Latency I gene
product (namely EBNA1 protein, EBERs or miR-BARTs), is
highly contradictory18,25,28–33 (reviewed in the Discussion). To
broaden these assorted but limited analyses, each of the
Latency I-associated genes were introduced into multiple
EBV-loss clones derived from several tumours. Figure 4
depicts data on Kem-BL clones; data from Mutu-BL and
Akata-BL clones are shown in Supplementary Figures 5 and
6, respectively. Lentiviral vectors34 were used to express
EBNA1 protein and the BART miRs in EBV-loss cells at levels
equivalent to those detected in EBV-positive BLs (Figures 4a
and e and Supplementary Figures 5a, e and 6a, e). A
derivative of pcDNA3 (pEKS10), containing 10 tandem
repeats of the EcoRI J region of the Akata strain EBV
genome (KC207813.1),29 was used to efficiently express
physiologically high levels of EBER RNAs (Figure 4c and
Supplementary Figures 5c and 6c).
Perhaps surprisingly, expression of neither EBNA1 nor
EBERs conferred any survival or growth advantage to EBV-
loss clones across three tumour backgrounds (Figures 4b and
d and Supplementary Figures 5b, d and 6b, d). In contrast to
published findings, EBER expression also did not upregulate
IL-10 and exogenously added IL-10 only modestly increased
BL cell survival (Supplementary Figure 7).35 Expression of
cluster 1 miR-BARTs, cluster 2 miR-BARTs or miR-BART-5
alone also conferred no protection to EBV-loss BL clones
(Figure 4f and Supplementary Figures 5f and 6f). A down-
regulation of PUMA by miR-BART-5 was observed in 293
cells, as reported previously,36 but no effect on BIM was
apparent37 (Supplementary Figure 8a). Critically, this down-
regulation of PUMA was not observed in EBV-loss BL cells
expressing cluster 1 miR-BARTs, cluster 2 miR-BARTs or
miR-BART-5 alone (Supplementary Figure 8b). To summarise,
no Latency I-associated EBV gene product alone could
restore apoptosis protection to EBV-loss BL clones,
suggesting that EBNA1, EBERs andmiR-BARTsmay function
cooperatively to inhibit apoptosis in BL.
To confirm that apoptosis protection is EBV mediated, we
sought to reinfect EBV-loss BL variants with recombinant (r)
EBV. These experiments are not trivial as reinfection with EBV
usually gives rise to the extensive Latency III infection rather
than a restricted Latency I pattern,38 and reinfectants often
harbour EBV as a small number of integrated copies, rather
than as multiple episomes typical of eBL.39 Two different
recombinant viruses were utilised – a recombinant derivative
of the Akata virus, Akata-GFP2 (Ak-V)40 and a variant of the
B95.8 prototype strain termed ΔCpWp-B95.8 (B-V), which is
forced to adopt a Latency I infection because of genomic
deletions spanning the Latency III-associated viral promoters,
Cp/Wp41 (Supplementary Figure 9). Reinfectants were
selected for functional analysis if 490% EBV-positive by
GFP or EBER-ISH, they contained 410 EBV genomes per
cell by DNA q-PCR and exhibited a Latency I infection as
determined by q-PCR, IF and immunoblotting (Figures 5a–d
and Supplementary Figure 10, and data not shown). A total of
nine Ak-V and six B-V reinfected cell lines across the Akata-
BL, Kem-BL and Mutu-BL tumour backgrounds met these
criteria.
Importantly, Ak-V could protect EBV-loss BL cells from
apoptotic stimuli; six cell lines were fully protected, two were
substantially protected and one (Akata n2) showed no
protection (Figures 5e and f and Supplementary Figure 11
and summarised in Table 2). Reinfection of EBV-loss BL
clones with B-V gave some apoptosis protection (except for
clone Akata n2), but these clones were significantly more
sensitive to apoptosis than the original EBV-positive counter-
parts. Therefore, EBV in a Latency I infection generally confers
apoptosis resistance to BL. The difference in apoptosis
protection conferred by the two viruses is intriguing and may
be due to one or more genes encoded within a 12 kb region of
the EBV BamHI A genomic locus, which is naturally deleted in
B95.8 and its derivative, B-V.42,43 These data highlight the
clonal variation and emphasises the need to analyse multiple
clones before drawing general conclusions.
Effect of EBV loss on cellular gene expression in BL. To
determine which cellular genes are modulated by EBV in
Latency I BL, RNA was extracted from EBV-positive and -loss
clones from four BL backgrounds (Akata-BL, Eli-BL, Mutu-BL
and Awia-BL) and microarray gene expression analysis was
undertaken. Surprisingly, no genes were significantly changed
more than twofold in EBV-loss compared with EBV-positive
clones across all tumours. Additionally, no differences in
Figure 3 In vivo and in vitro phenotype of isogenic EBV-positive and EBV-loss BL clones. (a) Tumorigenicity of BL clones in NSG mice. Kaplan–Meier survival plots
comparing survival in days post inoculation (P.I.) with isogenic EBV-positive (blue) or EBV-loss clones (red) derived from the parental EBV-positive BL cells lines as indicated.
Kem-BL clones, EBV-positive n= 12, EBV-loss n= 24, median survival (MS) 54versus 102 days. Mutu-BL clones, EBV-positive n= 19, EBV-loss n= 29, MS 63versus 113 days.
Awia-BL clones, EBV-positive n= 12, EBV-loss n= 12, MS 50versus 68 days. (b) Apoptotic cell death induced in response to BCR crosslinking with anti-IgM antibodies in
isogenic EBV-positive (P1–P3) versus EBV-loss (n1–n3) clones of Kem-BL, Mutu-BL and Awia-BL, 72 h post-treatment compared with vehicle-only controls. (c) Ionomycin-
induced cell death in isogenic EBV-positive (P1–P3) versus EBV-loss (n1–n3) clones of Kem-BL, Mutu-BL and Awia-BL (48 h), compared with vehicle-treated controls. Data are
the mean and standard deviation (S.D.) of pooled data from three independent experiments, each carried out in triplicate. Unpaired, two-tailed Student’s T-tests were carried out to
assess the significance of any difference in response between EBV-positive and EBV-loss clones from each background and P-values are indicated. Additionally, a two-way
analysis of variance (ANOVA) to compare all clones from all BL tumours showed that overall EBV has a highly significant effect on cell survival (Po0.0001) in response to both
ionomycin and IgM crosslinking
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steady-state expression of BCL-2 family transcripts were
observed (Supplementary Figure 12). We were also unable
to validate reports that expression levels of c-MYC, miR-127
and -199a or surface immunoglobulin correlate with the
presence of EBV (data not shown).30,44–46
To investigate the possibility that EBV imposes gene
expression changes only under conditions of stress, three
EBV-positive and EBV-loss clones of Kem-BL were treated
with ionomycin. As expected, ionomycin induced more cell
death in the EBV-loss clones than the EBV-positive clones
Figure 4 Apoptotic phenotype of EBV-loss Kem-BL clones re-expressing Latency I-associated genes. EBV-loss Kem-BL clones (n1–n3) re-expressing EBNA1 (a and b),
EBERs (c and d), miR-BARTs (e and f) or empty vector (controls), marked (+) and (− ), respectively, compared with isogenic EBV-loss (EBV − ve) and parental EBV-positive
cells (EBV +ve). (a) EBNA1 protein expression, blotted with human AMo serum with probing for actin used as a loading control. (b) Survival of ionomycin-treated EBNA1-
expressing EBV-loss BL cells compared with controls. (c) EBER expression was detected by Northern blotting using a probe to the EcoRI J fragment of the EBV genome, using
5 S as a loading control. (d) Survival of ionomycin-treated, EBER-expressing EBV-loss BL cells compared with controls. (e) Expression of mature BART miRs by q-PCR,
expressed from the Cluster 1 (top), Cluster 2 (middle) or miR-BART-5 only (bottom) constructs, relative to levels in Kem-BL. (f) Survival of ionomycin-treated miR-BART-
expressing EBV-loss BL cells compared with controls. All F-UTG-transduced cells in (a, b, e and f) induced with dox for 24 h before experiments were carried out. In apoptosis
assays (b, d and f), cell death was induced by treatment with ionomycin for 48 h. Data are representative of assays that were carried out in triplicate on three independent
occasions
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(36% versus 79% viability), with concordant cleavage of PARP
and increased caspase activation (Supplementary Figure 13).
In the presence of the pancaspase inhibitor Q-VD.OPh, all
ionomycin-treated clones remained 490% viable, permitting
RNA to be extracted post-treatment and microfluidic q-PCR
cards used to quantify changes in the expression of cell death-
associated transcripts.
Few changes were observed in response to ionomycin at
early time points. However, by 48 h, 15/93 transcripts were
found to be significantly differentially expressed in treated
EBV-loss clones compared with their untreated counterparts,
yet only 2/93 had changed significantly in EBV-positive clones
compared with their untreated counterparts (Figures 6a and b
and Supplementary Table 1). Although CASP8AP2 and
Figure 5 EBV gene expression and apoptosis sensitivity in EBV-loss clones of BL reinfected with Akata virus or ΔCpWp-B95.8 rEBVs. (a and b) Western blot analysis of
EBV latent protein expression in EBV-loss BL clones of Akata (An1-5), Kem (Kn1-3) and Mutu (Mn1-3) reinfected with Akata virus (Ak-V) (panel a, left) or ΔCpWp-B95.8 (B-V)
virus (panel b, right). Latency III LCLs express EBNA1, EBNA2 and LMP1, but Latency I reinfectants express only EBNA1 protein. EBV-loss cells that had not been reinfected
express only the cellular loading control, calregulin (CALR). (c and d) Expression of miR-BARTs in EBV-loss clones reinfected with Akata virus (Ak-V) (panel c, left) or ΔCpWp-
B95.8 virus (B-V) (panel d, right) quantified using stem-loop real-time PCR. Representative data for three miRNAs from BART cluster 1 (miR-BARTs 3, 15 and 5) and two from
BART cluster 2 (miR-BARTs 22 and 7) are shown relative to levels in the EBV-positive, Latency I cell line, Kem-BL. Note: the ΔCpWp-B95.8 virus genome harbours a deletion
spanning miR-BARTs 22 and 7 (denoted asΔ) as well as the 3′ end of the miR-BART-5 pre-miRNA. (e) Survival of EBV-loss clones reinfected with Akata virus (Ak-V, purple) after
challenge with ionomycin for 48 h relative to untreated controls and compared with EBV-positive parental BL cells (wt, blue) and EBV-loss BL cells from the same clonal
background (− ve, red). (f) Survival of EBV-loss BL clones reinfected withΔCpWp-B95.8 virus (B-V, purple) after challenge with ionomycin for 48 h relative to untreated controls
and compared with EBV-positive parental BL cells (wt, blue) and EBV-loss BL cells from the same clonal background (− ve, red). Data are presented as the mean and S.D. of
three independent experiments, each carried out in triplicate. Statistical significance was determined using an unpaired, two-tailed Student’s T-test, **Po0.01, *Po0.05
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DEDD2 were found to differ significantly in expression
between all EBV-loss and EBV-positive BL clones following
ionomycin treatment (Figure 6b), these changes did not
validate at the protein level (Supplementary Figure 14).
Comparing differentially expressed transcripts across all
groups and time points demonstrated that the response of all
BL clones to ionomycin was qualitatively similar, but delayed in
EBV-positive clones compared with EBV-loss clones
(Figure 6c).
These experiments indicate that the effects of EBV in BL are
not exclusively at the transcriptional level. Therefore, the
expression of 17 known apoptosis-associated proteins was
quantitated by immunoblotting in EBV-positive and EBV-loss
Kem-BL clones following treatment with ionomycin for 48 h in
the presence of Q-VD.OPh. Following exposure to death
stimuli, most proteins were similarly expressed in all clones,
irrespective of EBV status (Figure 6d). Strikingly though, the
proapoptotic BH3-only proteins, BIM and PUMA, were more
highly induced in EBV-loss clones than their EBV-positive BL
counterparts (Figure 6e). This difference was also evident at
early time points, detected by FACS and immunoblotting, but
only apparent following exposure to an apoptotic stimulus, not
under steady-state conditions (Figure 6f).
Functional analyses of the BCL-2 protein family in EBV-
positive versus EBV-loss clones in three endemic BL
backgrounds. To test if the upregulation of BIM and PUMA
following apoptotic stimulation was functionally relevant
across all BL backgrounds, a panel of variants based on
the BIMS sequence designed to recapitulate the binding and
neutralisation properties of various BH3-only proteins to their
BCL-2 prosurvival proteins was utilised.47,48 In this system,
the BIMS-4e protein is an inactive variant, unable to bind any
prosurvival BCL-2-like protein. The BIMS-wt protein can bind
and inhibit all BCL-2 prosurvival proteins, and therefore
recapitulates the action of BIM and PUMA, which are both
similarly potent inducers of apoptosis. The BIMS-BAD variant
can bind to BCL-2, BCL-XL and BCL-W; the BIMS-NOXA
variant can bind to MCL-1 and A1; and the BIMS-2a variant is
a more specific inhibitor of MCL-1 (Figures 7a and b and
Supplementary Table 2). The BIMS variants were expressed
in ten EBV-positive and EBV-loss clones across three BL
backgrounds.
These assays corroborated the earlier results that impli-
cated EBV in protecting against intrinsic apoptosis. EBV-loss
clones were generally more sensitive to all BIMS-BH3 variants
than their EBV-positive counterparts, suggesting that EBV is
not acting on any individual BCL-2-like prosurvival protein.
However, BIMS-wt, a functional mimetic of BIM and PUMA,
consistently and significantly sensitised EBV-loss clones to
cell death, compared with the EBV-positive BL controls
(Figures 7c–e). The Akata-BL clone n2 (which remained
apoptosis sensitive even after EBV reinfection) was an
exception, suggesting that this clone has acquired additional
genetic changes. For further verification, the phenotypic
consequence of shRNA depletion of BIM and PUMA in EBV-
loss and EBV-positive clones of Kem-BL and Akata-BL was
analysed. Only a modest reduction in BIM and PUMA protein
was achieved, yet this conferred protection from ionomycin-
induced apoptosis specifically to EBV-loss clones. In EBV-
positive BL clones, shRNAs targeting BIM and PUMA had no
effect on cell survival, likely because BIM and PUMA are
already repressed by the Latency I genes (Supplementary
Figures 15 and 16).
Overall, the data provide functional confirmation that the
loss of EBV-mediated inhibition of BIM and PUMA expression
and proapoptotic function is responsible for the increased
apoptosis sensitivity of EBV-loss BL clones. This indicates that
EBV Latency I genes act in a cooperative manner to inhibit
apoptosis by repressing the proapoptotic BH3-only proteins
BIM and PUMA.
Discussion
To our knowledge, this is the most extensive analysis of the
role of EBV in BL. The large-scale, single-cell cloning of BL cell
lines and isolation of only 61 spontaneous EBV-loss clones
from 41800 clones strongly indicate that EBV is highly
selected for in BL. Consistent with reports that EBV’s role in BL
is to protect cells from death stimuli,10,17,18,22,28 our study
showed that compared to isogenic EBV-positive counterparts,
EBV-loss clones from multiple tumour backgrounds are
consistently more sensitive to death stimuli that act through
the intrinsic apoptotic pathway. Additionally, EBV loss
Table 2 Summary of apoptosis sensitivity in EBV-loss clones derived from three
BL backgrounds reinfected with ΔCpWp-B95.8 rEBV or the Akata virus strain
Abbreviations: BL, Burkitt lymphoma; EBV, Epstein–Barr virus
Numbers denote percentage protection conferred, compared to parental EBV-
positive BL cells. The colour coding also reflects the extent to which the cells
were protected, as follows: dark green – complete protection (100%); light green
– substantial protection (51–75%), yellow – partial protection (26–50%); orange
– slight protection (1–25%); red – no protection (0). ND denotes not done, as
reinfectants on these BL backgrounds could not be generated
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significantly reduces the tumorigenic potential of BL cells in a
xenograft mouse model of BL. Collectively, these findings
demonstrate that EBV makes an ongoing contribution to the
aggressive neoplastic phenotype of BL and challenges the
idea that EBV only contributes to the early stages of
lymphomagenesis by a ‘hit-and-run’ mechanism.49,50 This
work also supports the idea that enforced loss of viral
genomes, perhaps in the future through drugs or EBV
genome-specific CRISPR (recently demonstrated in BL51),
could be useful clinically in the treatment of EBV-positive BLs.
Importantly, reinfection of EBV-loss cloneswith recombinant
Ak-V could fully restore apoptosis resistance, confirming that
EBV is directly responsible for the increased resistance to cell
death. Interestingly, B95.8-derived rEBV, which harbours a
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large genomic deletion, could partially, but never fully restore
apoptosis protection to BL cells. This genomic deletion spans
not only a number of the miR-BARTs42,43 but also a number of
transcripts of unknown function that appear to be highly
transcribed in latent BL cells.52,53 Therefore, it is likely that
genes encoded within the B95.8 deletion contribute to Latency
I-mediated protection from apoptosis. Further development of
rEBV genomes is required to decode the precise contribution
of these complex transcripts to BL.
No Latency I-encoded gene product alone (EBNA1, EBERs
or miR-BARTs) could restore apoptosis resistance to
EBV-loss BLs. This indicates a requirement for cooperation
between multiple genes, including transcripts from the B95.8
deletion. There is much debate in the literature in this regard.
EBNA1 is essential for virus genome maintenance and also
reported to function in cell survival in certain circumstances.31
EBER RNAs were shown to confer tumorigenicity to EBV-loss
Akata-BL in vivo and to enhance the growth properties of cells
in vitro, in part through upregulation of BCL-2 and IL-10.28,54
Yet we found no evidence that BCL-2 or IL-10 were more
highly expressed in EBER-expressing or EBV-positive cells
compared with EBV-loss cells. Consistent with our findings,
others reported that expression of EBERs alone did not
restore protection from apoptosis in Akata-BL cells in vitro, but
that coexpression of EBNA1 and EBERs rendered two EBV-
loss Akata-BL clones more tumorigenic in vivo.25 The authors
attributed this to increased EBER expression in the EBNA1-/
EBER-positive EBV-loss cells. However, an alternative inter-
pretation is that EBNA1 enhances the tumorigenicity of EBER-
expressing cells by functional cooperation. Another report
attributed apoptosis protection to the miR-BARTs,18 but the
considerable clonal variation (between cell lines and viruses)
in this study precludes firm conclusions. BART miRs have
been reported to downregulate PUMA in epithelial cells36
(a finding we could recapitulate in 293 cells), but consistent
with other groups,18,55,56 this downregulation was not appar-
ent in B-lineage-derived cell lines.
Our work implicates the BH3-only proteins BIM and PUMA
as the key cellular genes regulated by EBV in Latency I BL.
These proteins are critical initiators of the intrinsic apoptotic
pathway, able to bind and inhibit all BCL-2 prosurvival proteins
and also capable of directly activating the executioners of
apoptosis, BAX and BAK.3 In addition to the upregulation of
BIM and PUMA proteins after apoptosis induction in EBV-loss
cells, increased expression of BIM and PUMA transcripts was
also observed compared with EBV-positive cells, although this
did not reach statistical significance. Consistent with coopera-
tion between multiple EBV genes, we therefore hypothesise
that the repression of BIM and PUMA by EBV occurs at both
the protein and RNA levels and involves multiple molecular
mechanisms.
BART miRs are predicted to bind multiple sites in the 3′-
UTRs of BIM and PUMA36,37,55,56 and therefore likely inhibit
their translation. Additionally, EBERs have been shown to
activate AKT/PI3K signalling,57 which is important for BL cell
survival.58 Interestingly, tonic AKT/PI3K signalling has been
reported to suppress induction of PUMA and BIM, by both
transcriptional and post-translational mechanisms, and con-
sequently suppress apoptosis in leukaemia cells following
growth factor withdrawal.59 Furthermore, EBNA1 is able to
deplete cells of SMAD2,60,61 which can lead to inhibition of
PUMA expression through the TGF-β pathway.62,63 A recent
study showed that both RNA and DNA viruses, typified by
Semliki Forest virus and herpes simplex 1 virus, respectively,
control intrinsic apoptosis via regulation of PUMA.64 There-
fore, it is likely that Latency I EBV genes co-operate to regulate
PUMA and BIM both directly and indirectly and that multilateral
regulation of prodeath BH3s is critical and conserved in
human viruses.
The blocking of BIM and PUMA upregulation by EBV has
important implications for BL pathogenesis as it has been
shown that deregulated c-MYC expression can sensitise cells
to apoptosis and that this predisposition must be overcome for
BL to develop.65 Therefore, EBV infection of a preneoplastic
cell bearing a c-MYC chromosomal translocation would be
predicted to accelerate tumour development by blocking BIM
and PUMA upregulation. Our work opens up the possibility to
incorporate BH3-mimetic drugs (reviewed in Cory et al.66) into
the treatment regimen for EBV-positive BL to help improve
patient survival, which remains woeful in certain patient
groups.
Materials and Methods
Cell lines and cell maintenance. Akata-BL was a kind gift from Prof.
Kenzo Takada, Rael-BL and the lymphoblastoid cell line (LCL), Raji-BL, X50-7, were
kind gifts from Prof. George Klein. All other BL cell lines were established by Prof.
Alan Rickinson and co-workers. Jurkat clone E6.1 was from the European
Collection of Cell Cultures, HEK-293 cells were obtained from the American Tissue
Culture Collection (product number: ATCC CRL-1573) and 293FT cells (R700-07)
were from Life Technologies (Carlsbad, CA, USA). Clonal cell lines were established
Figure 6 Apoptosis-related transcript and protein expression in ionomycin+Q-VD.OPh-treated Kem-BL clones. (a) Volcano plot of changes in apoptosis-related transcripts in
EBV-loss BL clones treated with ionomycin and Q-VD.OPh for 48 h versus 0 h. The red box indicates significantly differentially regulated genes, as determined using cutoffs of FC
42 and P-valueo0.05. (b) Volcano plot of transcriptional changes in apoptosis-related genes in EBV-loss clones compared with their EBV-positive counterparts, treated with
ionomycin and Q-VD.OPh for 48 h. The red box indicates the significantly differentially regulated genes, as determined using cutoffs of FC42 and P-valueo0.05. (c) Box plot of
expression data for the 13 genes that are differentially regulated between EBV-loss clones treated for 48 versus 0 h, but not between EBV-positive and EBV-loss BL clones at
48 h. This subset appears to be an EBV-loss-specific gene expression signature. However, this comparison illustrates that this subset of genes is also upregulated in EBV-positive
BL clones, but to a lesser extent than in the clones that have lost EBV. (d) Summary of apoptosis-related protein expression in EBV-positive (blue) versus EBV-loss (red) clones of
Kem-BL treated with ionomycin and Q-VD.OPh for 48 h. Quantitation is relative to untreated Jurkat cells. Three proteins, which we found to be undetectable in Kem-BL, are
omitted (CFLAR, BAD and CASP8AP2). Data are presented as mean and S.D. of three separate experiments. Red circle in BCL-XL expression data represents one outlier result
from a single EBV-loss clone. (e) BIM and PUMA protein expression in EBV-positive (P1–P3) versus EBV-loss (n1–n3) Kem-BL clones treated with ionomycin and Q-VD.OPh for
48 h. Calregulin (CALR) was included as a loading control. Images are representative from three independent experiments. (f) Western blots showing BIM and PUMA expression
in EBV-positive Kem-P1 cells compared with EBV-loss Kem-n2 cells at 0, 3 or 6 h after treatment with ionomycin plus Q-VD.OPh, compared with the loading control, calregulin
(CALR). Expression data for all samples at all time points post exposure to ionomycin in hours (h) are expressed relative to EBV-positive BL clones at time 0. Statistical
significance was determined using a two-tailed Student’s T-test, **Po0.01, *Po0.05 and ns is not significant
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Figure 7 Apoptotic phenotype of EBV-positive and EBV-loss clones of BL clones expressing dox-inducible BIMS-BH3 variants. (a) Binding specificity of endogenous
prosurvival BCL-2 family members (green) to proapoptotic BH3-only proteins (black). (b) Binding specificity of BIMS-BH3 variants (red) to the different prosurvival BCL-2 family
members (green), dotted line indicates weak binding of BIMS-2a to A1/BFL1. (c–e) Apoptosis in EBV-positive (blue) versus EBV-loss clones (red) of Kem-BL (c), Akata-BL (d) and
Mutu-BL (e) expressing BIMS variants; BIMS-4e (negative control), BIMS-BAD, BIMS-2a, BIMS-NOXA and BIMS-wt. The left panel shows representative data (mean and S.D.) for a
single experiment and the right-hand panel shows mean values from three independent experiments. Induced cell death was calculated relative to cell death in untreated control
cells. All samples were treated with doxycycline to activate BIMS variant expression and induce cell death. Viable cells were defined as Annexin-V/propidium iodide (PI) double
negative. Statistical significance was determined using a two-tailed Student’s T-test to compare cell survival in each EBV-loss clone to the EBV-positive control in response to
each BIMS-BH3 variant. Where a variant induced significantly more death in an EBV-loss clone compared with the EBV-positive control, this is noted in the right-hand panel,
***Po0.001, **Po0.01 and *Po0.05. The average amount of death induced by ionomycin treatment in EBV-loss clones from each tumour background is denoted by a dashed
red line for comparison
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by single-cell cloning carried out as described previously.9 When referring to BL-
derived subclones, the prefix ‘P’ indicates an EBV-positive clone, whereas ‘n’
denotes a clone that has lost the virus. BL cell lines were maintained in RPMI-1640
supplemented with 10% FCS (Gibco, Gaithersburg, MD, USA), 6 mM glutamine,
1 mM pyruvate, 50 μM α-thioglycerol, 20 nM bathocupronine disulphonic acid and
8 μg/ml gentamycin (all Sigma, St Louis, MO, USA). All cells were routinely grown
at 37 °C in a humidified atmosphere containing 5% CO2.
Apoptosis assays. BL cells were seeded at 9x104/cm2 in the presence of
inducers or inhibitors of apoptosis, including: ionomycin (1 μg/ml, 48 h); etoposide
(50 μM, 24 h); Fas-activating CH11 antibodies (50 ng/ml, 24 h) (all Sigma);
roscovitine (50 μM, 48 h); staurosporine (250 nM, 24 h) (both Cell Signalling
Technologies (CST), Danvers, MA, USA); IgM crosslinking antibodies (5 μg/ml) (MP
Biomedicals, Santa Ana, CA, USA); the human cytokine, IL-10 (50–500 ng/ml)
(Peprotech, Rocky Hill, NJ, USA); Q-VD.OPh (20 μM) (MP Biomedicals) and/or a
vehicle-only control (DMSO) as stated, unless otherwise specified in figure legends.
Where inducible lentiviruses were used, gene of interest expression was induced by
the addition of 1 μg/ml doxycycline 24 h before the experiment set-up. All assays
were carried out in triplicate and on at least three occasions. Data are expressed as
mean and standard deviation of independent triplicates unless otherwise specified.
Cell viability was determined by dual staining of cells with Annexin-V-APC and PI or
PI staining alone and analysed by flow cytometry. Surface CD95 staining was
determined using the DX2-PE-CY7 (BioLegend, San Diego, CA, USA) as per the
manufacturer’s instructions. A minimum of 10 000 events was recorded for all
samples and data were analysed using the FlowJo Software (Treestar, OR, USA) or
Accuri C6 Software (Becton Dickinson, Franklin Lakes, NJ, USA).
Immunoblotting. Proteins in whole-cell lysates were separated by SDS-PAGE
and transferred to PVDF membranes that were probed using antibodies raised
against: EBNA1 (AMo serum); EBNA2 (PE2); LMP1 (CS1-4); BHRF1 (5B11);
β-actin (clone AC-15; Sigma); caspase-3, -7 and -9 (nos. 9662, 9492, 9502; all
CST); DEDD2/FLAME3 (14574; Proteintech, Chicago, IL, USA); PUMA (D30C10;
CST); BIM (no. 2819; CST); CFLAR (10394-1-AP; Proteintech); CASP8AP2 (PA5-
19954; Life Technologies); BID (no. 2002; CST); BAD (no. 9292; CST); BCL-2 (C-2;
Santa Cruz Biotechnology (SCBT, Dallas, TX, USA)); BCL-X (H-5; SCBT); MCL-1
(no. 4572; CST); cIAP1 (no. 4952; CST), Livin (D61D1; CST); Survivin (71G4B7;
CST); XIAP (3B6; CST); NOXA (114C307; Abcam, Cambridge, UK); BAK (N-20;
SCBT); and BAX (N-20; SCBT). Protein size analysis and densitometry were
carried out using the Chemidoc MP system equipped with the ImageLab v.5.2
Software (Bio-Rad, Hercules, CA, USA). Size markers were SeeBlue Plus 2 (Life
Technologies) and densitometry calculations were normalised to endogenous
control proteins, calregulin or β-actin.
Animal work. Mice were kept in specified pathogen-fee animal areas at the
Walter and Eliza Hall Institute of Medical Research (WEHI). All experiments
involving mice were conducted in accordance with the requirements of the WEHI
Animal Ethics Committee. Eight-week-old, female NSG (NOD.Cg-
Prkdcscidil2rgtm1Wjl/SzJ) mice were given intraperitoneal or subcutaneous injections
of BL cells diluted in PBS. Cell numbers used were 1 × 106 for Kem-BL, Awia-BL
and Mutu-BL clones or 1x107 for Akata-BL. Mice were monitored for signs of tumour
growth and killed when their tumour burden reached 1 cm3. Lymphoma cell
suspensions made from explanted tumour tissues were shown to be 499%
positive for human CD19 FACS (555415; BD Pharmingen, San Jose, CA, USA) to
confirm that tumours were derived from xenotransplanted BL cells.
Northern blotting. RNA was isolated using Trizol reagent, separated on
precast urea gels (both Life Technologies) and blotted onto nylon membranes.
Radio-labelled DNA probes were generated by PCR amplification of the EcoRI J
fragment of the EBV genome using forward primer 5′-TGCTAGGGAGGAG
ACGTGTGT-3′ and reverse primer 5′-GAATCCTGACTTGCAAATGCTCTA-3′,
followed by column purification and nick translation (Roche, Basel, Switzerland)
in the presence of 32P-labelled dCTP (Hartmann Analytic, Braunschweig,
Germany). Probe hybridisation and washes were carried out using the XpressHyb
System (Clontech, CA, USA) according to the manufacturer’s instructions.
Exposures were carried out at − 80 °C for 2–14 days.
Quantitative PCR analysis. Total RNA was prepared using miRVana RNA
Extraction Kit (Life Technologies) according to the manufacturer’s instructions.
Cellular apoptosis-related gene expression was quantified using TaqMan Low
Density Array human apoptosis panel cards (4378701; Life Technologies). Random
hexamer-primed cDNA was prepared using the qScript cDNA Supermix (Quanta
Biosciences, Beverly, MA, USA). All experiments were carried out in triplicate and
samples were run in triplicate. Data were analysed using Data Assist v.3.01 (Life
Technologies) using the ΔΔCt method, and then normalised to the mean of two
endogenous controls, ACTB and GAPDH. Absolute quantitation of EBV transcripts
and housekeeping controls were quantitated by real-time PCR relative to a DNA
plasmid standard to enable absolute copy numbers to be calculated. This method
and all the relevant primer-probe sets have been described elsewhere.53 Stem-loop
primed cDNA was prepared with miR-specific primers and TaqMan microRNA
Reverse Transcription Kit (Life Technologies) according to the manufacturer’s
guidelines and miR expression was quantified using commercially available TaqMan
primer/probe mixes (Life Technologies). EBV genome load was calculated by DNA
q-PCR. Briefly, DNA was extracted using the GenElute DNA Kit (Sigma) according
to the manufacturer’s instructions and 5 ng DNA was used per q-PCR assay.
Genome load was calculated by quantitating copies of the EBV polymerase gene
(BALF5) normalised to β-2-microglobulin (β2M), assuming two genomic copies of
β2M per cell. Each measurement was made in triplicate.
Plasmids, lentiviruses, recombinant EBVs and generation of
stable cell lines. The EBNA1 protein, clusters of BART miRs and BIMS-variant
proteins were expressed from an F-UTG-derived lentivirus, which constitutively
expresses GFP and drives expression of the gene of interest from a dox-inducible,
polII, Trex promoter, as described previously.67 Recombinant Akata virus (Ak-V)-
producing cells were a kind gift from Prof. Kenzo Takada and the CpWp-KO B95.8
virus (B-V) was developed by Dr. Rosemary Tierney. Detailed descriptions of all
recombinant EBVs and expression constructs are available in Supplementary
Information. All constructs were sequence verified.
Lentivirus containing supernatants were produced by transfecting 293FT cells (Life
Technologies) with the expression constructs of interest alongside the envelope
plasmid, pMD2.G, and the packaging plasmid, psPax2, using Lipofectamine 2000
(Life Technologies). Infectious virus stocks produced from B-V BAC-carrying 293
clones by BZLF1/BALF4 transfection68 or from Ak-V-infected BL cells by crosslinking
surface IgG40 as described previously. Before EBV infection, EBV-loss BL clones
were transduced with an expression construct expressing the EBV receptor, human
CD21, to enhance the infection efficiency.69
Statistical analysis. For BIMs-BH3 variant functional assays, reinfection
studies, q-PCR and immunoblot gene expression analyses the significance of
differences between cell lines were calculated using an unpaired, two-tailed,
Student’s T-test. For apoptosis assays to characterise the effect of EBV loss,
unpaired, two-tailed Student’s T-tests were carried out on clones from each
background. Additionally, the difference in cell survival between all EBV-positive
clones and all EBV-loss clones across different BL backgrounds was analysed by
two-way ANOVA. Survival comparisons of mouse cohorts were calculated using log-
rank (Mantel–Cox) analysis. T-tests, Mantel–Cox and ANOVA analyses were carried
out in the GraphPad Prism 5.0 Software (La Jolla, CA, USA). Differences were
considered significant where the P-value fell below 0.05 and were classified as
follows: *Po0.05, **Po0.01, ***Po0.001 and nsP40.05 (not significant).
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